We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Janssen, GlaxoSmithKline and NewLink Genetics will be safe under a law that protects companies producing treatments to combat health emergencies. Read More
The U.S. Supreme Court declined to hear an appeal of a ruling that had struck down an Arizona law banning the use of the abortion drug RU-486 alongside misoprostol, a decision that effectively confirms earlier court positions upholding the FDA’s off-label drug use policy. Read More
Novartis’ cancer drug Afinitor failed to significantly increase survival rates for patients with a rare type of advanced breast cancer, casting further doubt on the drugmaker’s efforts to expand uses of the blockbuster therapy. Read More
British healthcare cost evaluators have reversed course and are now recommending reimbursement for three ulcerative colitis drugs: AbbVie’s Humira and Merck’s Remicade and Simponi. Read More
A German healthcare watchdog questioned the efficacy of Bayer’s Eylea for a third time, which could affect the reimbursement price of the profitable eye drug. Read More
The Senate late Saturday approved a spending bill that gives the FDA nearly $1.7 billion in drug and biologic regulatory funding, a $48 million increase over current levels. Read More
Generic drug prices in Canada have fallen significantly in recent years, even while they continue to trend higher than their international cohorts, says a new Canadian government report. Read More
The FDA has approved Eli Lilly’s Cyramza to treat the most common type of lung cancer, the latest effort by the drugmaker to vastly increase uses of the oncology drug. Read More